Pneumonia, Bacterial
Conditions
Keywords
Emergency department, Antibiotics, Sputum
Brief summary
Antibiotic resistance has been identified by the WHO as one of the biggest threats to the health of the world population. In Denmark, there has been an increasing focus on optimizing antibiotic consumption in recent years, but despite significant efforts, total consumption has increased in the hospital sector, especially regarding consumption and in the use of broad-spectrum antibiotics. Currently, a pneumonia diagnosis is primarily based on clinical symptoms such as cough, shortness of breath, chest pain, fever and sputum production, combined with X-ray of the lungs, relevant blood tests and microbiological analysis of sputum samples. X-ray is however an imprecise diagnostic tool, and sputum assays responses are available after 2 days. Sputum can be cultivated to determine the bacterial agent. However, the sputum samples are often of poor quality and many patients cannot deliver a sample. A recently published Danish study shows, that only half of the patients at the ED have sputum samples collected for culturing and none of them had the antibiotic treatment adjusted based on the microbiological results of the sputum. This study's hypothesis is that point-of-care-polymerase chain reaction (POC-PCR) is superior to standard care on the prescription of targeted pneumonia treatment.
Detailed description
The diagnosis of pneumonia is challenged by nonspecific symptoms, uncertain diagnostic methods, poor prognostic tools and waiting time for test results up to several days. A patient's length of stay in a Danish Emergency Department rarely exceeds 48 hours. Within this period the patient is examined, treated and discharged either home or to another department. Therefore, rapid molecular detection of respiratory pathogens is needed to add value to the management of the diagnostics of pneumonia and could reduce the initial use of antibiotics. Molecular diagnostic tests based on polymerase chain reaction (PCR) assays generate high sensitive analyses in one hour from specimen collection. The Biofire® FilmArray® Pneumonia Panel plus (Biomérieux) can identify 18 bacterial agents including 3 atypical pathogens 9 viruses and 7 antimicrobial resistance genes. This point-of-care (POC) test is promising, as bacterial pathogens often coexist with viruses or are identified with mixed infections. However, the high specificity of molecular diagnostics can challenge the interpretation of clinically significant agents and demands interpretation by highly qualified specialists. Therefore, the POC-PCR combined with advice from a microbiologist has the potential to optimize therapeutic regimens and reduce prescriptions of inappropriate broad-spectrum antibiotics in the initial management of pneumonia. This study aims to * investigate how effective the addition of POC-PCR analysis of sputum is to the diagnostic set-up for community-acquired pneumonia on antibiotic prescription at 4 hours after admission without consequent adverse advents * to identify the effect of POC-PCR on prescribed antibiotic treatment 48 hours after admission and 24 hours after discharge * to investigate the agreement between POC-PCR and sputum culture on microbiological analysis
Interventions
DIAGNOSTIC_TESTPOC-PCR
The result of the POC-PCR will be presented by the study assistant to the treating physician within four hours upon admission. The treating physician will along with the result receive a recommended action list, developed by microbiologists.
Sponsors
University of Southern Denmark
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Masking description
The patients will be blinded, and the investigator will be blinded to POC-PCR results, data management and analysis, but not allocation. Outcome assessors will not be blinded
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Emergency department patients suspected of pneumonia by the attending physician and with at least one of the following symptoms: dyspnea, cough, expectoration, chest tightness or fever and indication for chest x-ray
Exclusion criteria
* If the attending physician considers that participation will delay a life-saving treatment or patient needs direct transfer to the intensive care unit. * Admission within the last 14 days * Verified COVID-19 disease within 14 days before admission * Pregnant women * Severe immunodeficiencies: Primary immunodeficiencies and secondary immunodeficiencies (HIV positive CD4 \<200, Patients receiving immunosuppressive treatment (ATC L04A), Corticosteroid treatment (\>20 mg/day prednisone or equivalent for \>14 days within the last 30 days), Chemotherapy within 30 days)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Antibiotic treatment at 4-hour plan | 4 hours after admission | The primary outcome is to determine the effectiveness of POC-PCR sputum analysis on antibiotic prescription, the treatment will either be registered as targeted or non-targeted antibiotic treatment at four hours after admission. This is a binary outcome. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 30-days mortality | 30 days from the admission to the emergency department | Mortality within 30 days from admission to the Emergency Department |
| Readmission | within 30 days from the discharge to the hospital | If a subject is admitted over a 30 day period after the current hospitalization discharge measured as a binary outcome Re-admissions/not re-admissions. |
| In-hospital mortality | within 60 days from admission to the emergency department | Patient mortality during the current hospitalization. Binary outcome - Died/ Not died |
| Antibiotic treatment at 48 hour | 48 hours after admission | The treatment will either be registered as targeted or non-targeted antibiotic treatment 48 hours after admission. This is a binary outcome. |
| Antibiotic treatment at discharge from hospital | 24 hours after hospital discharge | The treatment will either be registered as a targeted or non-targeted antibiotic treatment after the patient is discharged from the hospital. This is a binary outcome. |
| Bacterial agents and viruses from the microbiological results | Within the first 7 days from specimen collection | The bacterial agents and viruses from the Biofire® FilmArray® Pneumonia Panel plus (Biomérieux) and standard sputum culture for the two microbiological analysis will be presented as descriptive statistics. |
| Intensive care unit (ICU) treatment | within 60 days from admission to the emergency department | Transfer to the intensive care unit will be recorded during the current hospitalization as a binary variable (transferred/not-transferred) |
| Length of hospital stay | within 60 days from current admission to the emergency department | Defined as the time (in days) spent in hospital during the current admission. Measured in days from admission to hospital discharge. Discharge date minus admission date. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Number of clostridium infections | measured 40 days after discharge from the emergency department | Identify through patient records if the patient was infected with clostridium difficille, binary outcome yes/no |
| Procalcitonin (PCT), Soluble Urokinase Plasminogen Activator Receptor (suPAR), YKL-40 and Krebs von den Lungen (KL-6) | results within 4 hour from admission | Measurement of serum PCT and suPAR are collected in connection to routine blood tests within 1 hour from admission |
| 90 days mortality | Within 90 days from admission to emergency department | binary |
| CURB-65 score for pneumonia severity | within 4 hours from admission | Confusion of new onset, Blood Urea nitrogen greater than 7 mmol/L (19 mg/dL), respiratory rate of 30 breaths per minute or greater, blood pressure less than 90 mmHg systolic or diastolic blood pressure 60 mmHg or less and age 65 or older |
| Pneumonia severity index (PSI) | within 4 hours from admission | Risk classes to predict the severity of pneumonia. Scores are given based on demographics, comorbidity, clinical measurements and physical Exam Findings (\<70 = Risk Class II, 71-90 = Risk Class III, 91-130 = Risk Class IV, \>130 = Risk Class V) |
Countries
Denmark
Outcome results
None listed